Publications by authors named "E R Birnbaum"
Neuroinflammation is a key pathological hallmark of Alzheimer's disease (AD). Investigational and FDA approved drugs targeting inflammation already exist, thus drug repurposing for AD is a suitable approach. BT-11 is an investigational drug that reduces inflammation in the gut and improves cognitive function.
View Article and Find Full Text PDFCompared with other health disciplines, there is a stagnation in technological innovation in the field of clinical neuropsychology. Traditional paper-and-pencil tests have a number of shortcomings, such as low-frequency data collection and limitations in ecological validity. While computerized cognitive assessment may help overcome some of these issues, current computerized paradigms do not address the majority of these limitations.
View Article and Find Full Text PDFBackground: Total neoadjuvant therapy for locally advanced rectal cancer may include induction chemotherapy and chemoradiation or short-course radiotherapy and consolidative chemotherapy.
Methods: Patients with clinical stage 2 or 3 rectal cancer who received induction chemotherapy followed by long-course chemoradiation at the University of Colorado (2016-2020) or short-course radiotherapy followed by consolidative chemotherapy at Washington University (2017-2020) were assessed.
Results: Eighty-four patients received induction chemotherapy and chemoradiation and 83 received short-course radiotherapy and consolidative chemotherapy.
Article Synopsis
- The study investigates the effects of adjuvant chemotherapy on survival rates in rectal cancer patients who have achieved a pathologic complete response after neoadjuvant chemoradiotherapy and total mesorectal excision.
- It included data from over 20,000 patients, focusing on those who received or did not receive adjuvant therapy, with findings indicating a significant survival advantage for those who underwent the additional treatment.
- Results showed that patients who received adjuvant chemotherapy had a 5, 10, and 14-year survival rate of 93%, 85%, and 83%, respectively, compared to 87%, 67%, and 51% for those who did not receive it, suggesting a critical benefit
Introduction: Neighborhood measures of social vulnerability encompassing multiple sociodemographic factors can be used to quantify disparities in outcomes. We hypothesize patients with high Social Vulnerability Index (SVI) are at increased risk of morbidity following colectomy.
Methods: We used local 2012-2017 National Surgical Quality Improvement Program (NSQIP) data to study colectomy patients, examining associations between SVI and postoperative outcomes.